Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 5 Gastrointestinal 5 Other solid neoplasm 2 Thoracic 1 Sarcoma 1 Gynecologic 1 CNS 1 Breast 1

Conditions

Interventions

Temozolomide 299 Radiotherapy 219 Bevacizumab 139 Carboplatin 91 Cyclophosphamide 88 Etoposide 82 Filgrastim 72 Vincristine 69 Irinotecan 69 Magnetic Resonance Spectroscopy 65 Cisplatin 59 Radiation 58 Radiosurgery 53 Surgical Procedures, Operative 41 Peripheral Blood Stem Cell Transplantation 40 Topotecan 39 Doxorubicin 39 Lomustine 37 Carmustine 36 sargramostim 35 Granulocyte Colony-Stimulating Factor 35 Melphalan 34 Nivolumab 32 Chemotherapy, Adjuvant 32 Radiotherapy, Intensity-Modulated 29 Isotretinoin 29 Everolimus 29 Erlotinib Hydrochloride 27 Thiotepa 25 Vorinostat 24

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × tivozanib × CNS × Clear all

NCT01846871 2019-01-08

Tivozanib for Recurrent Glioblastoma

Massachusetts General Hospital

Phase 2 Completed

10 enrolled 13 charts

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡